Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827163 | 0.86 | GSK3B (0.51) | KDM4EMTNR1AMTNR1BMAPK8 | |
| SCHEMBL15765677 | 0.85 | PTPN11 (0.44) | DHODHPTPN11KDM4EPOLB | |
| SCHEMBL17733172 | 0.83 | CYP1A2 (0.50) | PLA2G2AKDM4E | |
| SCHEMBL17733183 | 0.82 | PTPN1 (0.42) | KDM4E | |
| SCHEMBL10137154 | 0.81 | PTPN11 (0.44) | DHODHPTPN11 | |
| SCHEMBL10070479 | 0.79 | PTPN11 (0.40) | DHODHPLA2G2APTPN11KDM4E | |
| SCHEMBL25876699 | 0.79 | LRRK2 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL17733182 | 0.79 | FABP3 (0.47) | PLA2G2AKDM4EPOLBFABP3FABP4 | |
| SCHEMBL15452270 | 0.78 | PTPN11 (0.46) | DHODHPTPN11KDM4E | |
| SCHEMBL10293152 | 0.78 | KDM4E (0.41) | PLA2G2AHTR2AHTR2CHTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643905-B2 | Phenylnaphthol derivatives | TOKUYAMA CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160130203-A1 | NOVEL PHENYLNAPHTHOL DERIVATIVES | TOKUYAMA CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3018115-A1 | NOVEL PHENYL NAPTHOL DERIVATIVE | Tokuyama Corporation (JP) | 2016-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130203-A1 | NOVEL PHENYLNAPHTHOL DERIVATIVES | AHR, ARL1, PAH | DHODH 1419/4885PLA2G2A 2455/4885PTPN11 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.